Literature DB >> 29432556

A High-risk Haplotype for Premature Menopause in Childhood Cancer Survivors Exposed to Gonadotoxic Therapy.

Russell J Brooke1, Cindy Im2, Carmen L Wilson1, Matthew J Krasin1, Qi Liu2, Zhenghong Li1, Yadav Sapkota1, WonJong Moon1, Lindsay M Morton3, Gang Wu1, Zhaoming Wang1, Wenan Chen1, Rebecca M Howell4, Gregory T Armstrong1, Smita Bhatia5, Sogol Mostoufi-Moab6, Kristy Seidel7, Stephen J Chanock3, Jinghui Zhang1, Daniel M Green1, Charles A Sklar8, Melissa M Hudson1, Leslie L Robison1, Wassim Chemaitilly1, Yutaka Yasui1.   

Abstract

Background: Childhood cancer survivors are at increased risk of therapy-related premature menopause (PM), with a cumulative incidence of 8.0%, but the contribution of genetic factors is unknown.
Methods: Genome-wide association analyses were conducted to identify single nucleotide polymorphisms (SNPs) associated with clinically diagnosed PM (menopause < 40 years) among 799 female survivors of childhood cancer participating in the St. Jude Lifetime Cohort Study (SJLIFE). Analyses were adjusted for cyclophosphamide equivalent dose of alkylating agents and ovarian radiotherapy (RT) dose (all P values two-sided). Replication was performed using self-reported PM in 1624 survivors participating in the Childhood Cancer Survivor Study (CCSS).
Results: PM was clinically diagnosed in 30 (3.8%) SJLIFE participants. Thirteen SNPs (70 kb region of chromosome 4q32.1) upstream of the Neuropeptide Receptor 2 gene (NPY2R) were associated with PM prevalence (minimum P = 3.3 × 10-7 for rs9999820, all P < 10-5). Being a homozygous carrier of a haplotype formed by four of the 13 SNPs (seen in one in seven in the general population but more than 50% of SJLIFE clinically diagnosed PM) was associated with markedly elevated PM prevalence among survivors exposed to ovarian RT (odds ratio [OR] = 25.89, 95% confidence interval [CI] = 6.18 to 138.31, P = 8.2 × 10-6); this finding was replicated in an independent second cohort of CCSS in spite of its use of self-reported PM (OR = 3.97, 95% CI = 1.67 to 9.41, P = .002). Evidence from bioinformatics data suggests that the haplotype alters the regulation of NPY2R transcription, possibly affecting PM risk through neuroendocrine pathways. Conclusions: The haplotype captures the majority of clinically diagnosed PM cases and, with further validation, may have clinical application in identifying the highest-risk survivors for PM for possible intervention by cryopreservation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29432556      PMCID: PMC6093389          DOI: 10.1093/jnci/djx281

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  27 in total

1.  A comparison of bayesian methods for haplotype reconstruction from population genotype data.

Authors:  Matthew Stephens; Peter Donnelly
Journal:  Am J Hum Genet       Date:  2003-10-20       Impact factor: 11.025

Review 2.  Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults.

Authors:  Richard A Anderson; Rod T Mitchell; Thomas W Kelsey; Norah Spears; Evelyn E Telfer; W Hamish B Wallace
Journal:  Lancet Diabetes Endocrinol       Date:  2015-04-12       Impact factor: 32.069

3.  Attenuation of luteinizing hormone surges in neuropeptide Y knockout mice.

Authors:  M Xu; J W Hill; J E Levine
Journal:  Neuroendocrinology       Date:  2000-11       Impact factor: 4.914

4.  Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.

Authors:  Lindsay M Morton; Joshua N Sampson; Gregory T Armstrong; Ting-Huei Chen; Melissa M Hudson; Eric Karlins; Casey L Dagnall; Shengchao Alfred Li; Carmen L Wilson; Deo Kumar Srivastava; Wei Liu; Guolian Kang; Kevin C Oeffinger; Tara O Henderson; Chaya S Moskowitz; Todd M Gibson; Diana M Merino; Jeannette R Wong; Sue Hammond; Joseph P Neglia; Lucie M Turcotte; Jeremy Miller; Laura Bowen; William A Wheeler; Wendy M Leisenring; John A Whitton; Laurie Burdette; Charles Chung; Belynda D Hicks; Kristine Jones; Mitchell J Machiela; Aurelie Vogt; Zhaoming Wang; Meredith Yeager; Geoffrey Neale; Matthew Lear; Louise C Strong; Yutaka Yasui; Marilyn Stovall; Rita E Weathers; Susan A Smith; Rebecca Howell; Stella M Davies; Gretchen A Radloff; Kenan Onel; Amy Berrington de González; Peter D Inskip; Preetha Rajaraman; Joseph F Fraumeni; Smita Bhatia; Stephen J Chanock; Margaret A Tucker; Leslie L Robison
Journal:  J Natl Cancer Inst       Date:  2017-11-01       Impact factor: 13.506

5.  The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Vikki G Nolan; Pamela J Goodman; John A Whitton; DeoKumar Srivastava; Wendy M Leisenring; Joseph P Neglia; Charles A Sklar; Sue C Kaste; Melissa M Hudson; Lisa R Diller; Marilyn Stovall; Sarah S Donaldson; Leslie L Robison
Journal:  Pediatr Blood Cancer       Date:  2013-08-12       Impact factor: 3.167

6.  Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.

Authors:  Sogol Mostoufi-Moab; Kristy Seidel; Wendy M Leisenring; Gregory T Armstrong; Kevin C Oeffinger; Marilyn Stovall; Lillian R Meacham; Daniel M Green; Rita Weathers; Jill P Ginsberg; Leslie L Robison; Charles A Sklar
Journal:  J Clin Oncol       Date:  2016-07-05       Impact factor: 44.544

7.  Acute ovarian failure in the childhood cancer survivor study.

Authors:  Wassim Chemaitilly; Ann C Mertens; Pauline Mitby; John Whitton; Marilyn Stovall; Yutaka Yasui; Leslie L Robison; Charles A Sklar
Journal:  J Clin Endocrinol Metab       Date:  2006-02-21       Impact factor: 6.134

8.  Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation.

Authors:  W Hamish B Wallace; Alice Grove Smith; Thomas W Kelsey; Angela E Edgar; Richard A Anderson
Journal:  Lancet Oncol       Date:  2014-08-14       Impact factor: 41.316

9.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

10.  Integrative analysis of 111 reference human epigenomes.

Authors:  Anshul Kundaje; Wouter Meuleman; Jason Ernst; Misha Bilenky; Angela Yen; Alireza Heravi-Moussavi; Pouya Kheradpour; Zhizhuo Zhang; Jianrong Wang; Michael J Ziller; Viren Amin; John W Whitaker; Matthew D Schultz; Lucas D Ward; Abhishek Sarkar; Gerald Quon; Richard S Sandstrom; Matthew L Eaton; Yi-Chieh Wu; Andreas R Pfenning; Xinchen Wang; Melina Claussnitzer; Yaping Liu; Cristian Coarfa; R Alan Harris; Noam Shoresh; Charles B Epstein; Elizabeta Gjoneska; Danny Leung; Wei Xie; R David Hawkins; Ryan Lister; Chibo Hong; Philippe Gascard; Andrew J Mungall; Richard Moore; Eric Chuah; Angela Tam; Theresa K Canfield; R Scott Hansen; Rajinder Kaul; Peter J Sabo; Mukul S Bansal; Annaick Carles; Jesse R Dixon; Kai-How Farh; Soheil Feizi; Rosa Karlic; Ah-Ram Kim; Ashwinikumar Kulkarni; Daofeng Li; Rebecca Lowdon; GiNell Elliott; Tim R Mercer; Shane J Neph; Vitor Onuchic; Paz Polak; Nisha Rajagopal; Pradipta Ray; Richard C Sallari; Kyle T Siebenthall; Nicholas A Sinnott-Armstrong; Michael Stevens; Robert E Thurman; Jie Wu; Bo Zhang; Xin Zhou; Arthur E Beaudet; Laurie A Boyer; Philip L De Jager; Peggy J Farnham; Susan J Fisher; David Haussler; Steven J M Jones; Wei Li; Marco A Marra; Michael T McManus; Shamil Sunyaev; James A Thomson; Thea D Tlsty; Li-Huei Tsai; Wei Wang; Robert A Waterland; Michael Q Zhang; Lisa H Chadwick; Bradley E Bernstein; Joseph F Costello; Joseph R Ecker; Martin Hirst; Alexander Meissner; Aleksandar Milosavljevic; Bing Ren; John A Stamatoyannopoulos; Ting Wang; Manolis Kellis
Journal:  Nature       Date:  2015-02-19       Impact factor: 69.504

View more
  8 in total

1.  Predicting acute ovarian failure in female survivors of childhood cancer: a cohort study in the Childhood Cancer Survivor Study (CCSS) and the St Jude Lifetime Cohort (SJLIFE).

Authors:  Rebecca A Clark; Sogol Mostoufi-Moab; Yutaka Yasui; Ngoc Khanh Vu; Charles A Sklar; Tarek Motan; Russell J Brooke; Todd M Gibson; Kevin C Oeffinger; Rebecca M Howell; Susan A Smith; Zhe Lu; Leslie L Robison; Wassim Chemaitilly; Melissa M Hudson; Gregory T Armstrong; Paul C Nathan; Yan Yuan
Journal:  Lancet Oncol       Date:  2020-02-14       Impact factor: 41.316

Review 2.  Current and coming challenges in the management of the survivorship population.

Authors:  Eric J Chow; Kirsten K Ness; Gregory T Armstrong; Nickhill Bhakta; Jennifer M Yeh; Smita Bhatia; Wendy Landier; Louis S Constine; Melissa M Hudson; Paul C Nathan
Journal:  Semin Oncol       Date:  2020-03-04       Impact factor: 4.929

3.  Genome-wide Association Studies Reveal Novel Locus With Sex-/Therapy-Specific Fracture Risk Effects in Childhood Cancer Survivors.

Authors:  Cindy Im; Nan Li; Wonjong Moon; Qi Liu; Lindsay M Morton; Wendy M Leisenring; Rebecca M Howell; Eric J Chow; Charles A Sklar; Carmen L Wilson; Zhaoming Wang; Yadav Sapkota; Wassim Chemaitilly; Kirsten K Ness; Melissa M Hudson; Leslie L Robison; Smita Bhatia; Gregory T Armstrong; Yutaka Yasui
Journal:  J Bone Miner Res       Date:  2020-12-30       Impact factor: 6.741

4.  Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function.

Authors:  Anne-Lotte L F van der Kooi; Marloes van Dijk; Linda Broer; Marleen H van den Berg; Joop S E Laven; Flora E van Leeuwen; Cornelis B Lambalk; Annelies Overbeek; Jacqueline J Loonen; Helena J van der Pal; Wim J Tissing; Birgitta Versluys; Dorine Bresters; Catharina C M Beerendonk; Cécile R Ronckers; Margriet van der Heiden-van der Loo; Gertjan L Kaspers; Andrica C H de Vries; Leslie L Robison; Melissa M Hudson; Wassim Chemaitilly; Julianne Byrne; Claire Berger; Eva Clemens; Uta Dirksen; Jeanette Falck Winther; Sophie D Fosså; Desiree Grabow; Riccardo Haupt; Melanie Kaiser; Tomas Kepak; Jarmila Kruseova; Dalit Modan-Moses; Saskia M F Pluijm; Claudia Spix; Oliver Zolk; Peter Kaatsch; Jesse H Krijthe; Leontien C Kremer; Yutaka Yasui; Russell J Brooke; André G Uitterlinden; Marry M van den Heuvel-Eibrink; Eline van Dulmen-den Broeder
Journal:  Hum Reprod       Date:  2021-03-18       Impact factor: 6.918

5.  Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study.

Authors:  M E Madeleine van der Perk; Linda Broer; Yutaka Yasui; Leslie L Robison; Melissa M Hudson; Joop S E Laven; Helena J van der Pal; Wim J E Tissing; Birgitta Versluys; Dorine Bresters; Gertjan J L Kaspers; Andrica C H de Vries; Cornelis B Lambalk; Annelies Overbeek; Jacqueline J Loonen; Catharina C M Beerendonk; Julianne Byrne; Claire Berger; Eva Clemens; Uta Dirksen; Jeanette Falck Winther; Sophie D Fosså; Desiree Grabow; Monica Muraca; Melanie Kaiser; Tomáš Kepák; Jarmila Kruseova; Dalit Modan-Moses; Claudia Spix; Oliver Zolk; Peter Kaatsch; Jesse H Krijthe; Leontien C M Kremer; Russell J Brooke; Jessica L Baedke; Ron H N van Schaik; John N van den Anker; André G Uitterlinden; Annelies M E Bos; Flora E van Leeuwen; Eline van Dulmen-den Broeder; Anne-Lotte L F van der Kooi; Marry M van den Heuvel-Eibrink
Journal:  Cancers (Basel)       Date:  2021-09-13       Impact factor: 6.639

6.  White paper: Oncofertility in pediatric patients with Wilms tumor.

Authors:  M E Madeleine van der Perk; Nicholas G Cost; Annelies M E Bos; Robert Brannigan; Tanzina Chowdhury; Andrew M Davidoff; Najat C Daw; Jeffrey S Dome; Peter Ehrlich; Norbert Graf; James Geller; John Kalapurakal; Kathleen Kieran; Marcus Malek; Mary F McAleer; Elizabeth Mullen; Luke Pater; Angela Polanco; Rodrigo Romao; Amanda F Saltzman; Amy L Walz; Andrew D Woods; Marry M van den Heuvel-Eibrink; Conrad V Fernandez
Journal:  Int J Cancer       Date:  2022-05-11       Impact factor: 7.316

7.  Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol.

Authors:  Anne-Lotte L F van der Kooi; Eva Clemens; Linda Broer; Oliver Zolk; Julianne Byrne; Helen Campbell; Marleen van den Berg; Claire Berger; Gabriele Calaminus; Uta Dirksen; Jeanette Falck Winther; Sophie D Fosså; Desiree Grabow; Riccardo Haupt; Melanie Kaiser; Tomas Kepak; Leontien Kremer; Jarmila Kruseova; Dalit Modan-Moses; Andreas Ranft; Claudia Spix; Peter Kaatsch; Joop S E Laven; Eline van Dulmen-den Broeder; André G Uitterlinden; Marry M van den Heuvel-Eibrink
Journal:  BMC Cancer       Date:  2018-09-26       Impact factor: 4.430

8.  Clinical ascertainment of health outcomes in Asian survivors of childhood cancer: a systematic review.

Authors:  Long Hin Jonathan Poon; Chun-Pong Yu; Liwen Peng; Celeste Lom-Ying Ewig; Hui Zhang; Chi-Kong Li; Yin Ting Cheung
Journal:  J Cancer Surviv       Date:  2019-05-04       Impact factor: 4.442

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.